SAN ANTONIO – In a global study involving more than 5,000 women, risk-reducing surgeries significantly improved survival and ...

SAN DIEGO – Gilead Sciences and Arcellx's autologous B-cell maturation antigen (BCMA)-directed CAR T-cell therapy ...

NEW YORK – Leapfrog Bio on Wednesday said it will move on to a Phase II trial of its bromodomain and extra-terminal domain (BET) protein inhibitor LFB-190 in lung, colon, and bladder cancer after ...

SpliceBio aims to begin a study testing its protein splicing gene therapy in the first half of 2025, now that the FDA has cleared its IND.

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.

The data suggest that multiple myeloma patients on Janssen's CAR T-cell therapy lived longer than on BMS's but experienced ...

The new Future Medicines Institute, based at Queen's University Belfast, is backed by government and industry.